{ "run": { "id": "cmnr139ti034fp658fkiqw012", "region": "US", "assetId": "cmnr139c8033zp658o3905cbz", "ticker": "CVS", "snapshotId": "cmnr139ng0346p65848pcg9ct", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:22.900Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr139ng0346p65848pcg9ct", "assetId": "cmnr139c8033zp658o3905cbz", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 78.79, "dayLow": 77.72, "volume": 5295936, "dayHigh": 78.86, "currency": "USD", "prevClose": 78.22, "week52Low": 58.35, "week52High": 85.15 }, "fundamentals": { "pe": 29.4905063291139, "beta": 0.748448607056299, "epsTTM": 3.16, "fcfTTM": 11953000000, "growth": { "epsYoy": -0.6185286103542235, "revenueYoy": 0.07847986502471775 }, "sector": "Retail-Drug Stores and Proprietary Stores", "margins": { "net": 0.02940616471683344, "gross": 0.1550276079460111, "operating": 0.04977892487676913 }, "website": "http://cvshealth.com/", "industry": "Managed healthcare", "pegRatio": -0.623038866108041, "ebitdaTTM": 14799000000, "forwardPe": 11.187274909964, "marketCap": 86382523283, "totalCash": 8453000000, "totalDebt": 60502000000, "debtEquity": 0.735816376821798, "quickRatio": 0.5679993686014522, "revenueTTM": 47269000000, "companyName": "CVS HEALTH Corp", "priceToBook": 1.71443987940826, "currentRatio": 0.8423984124836513, "dividendYield": 0.023800706136689, "returnOnAssets": 0.005482412892741917, "returnOnEquity": 0.0584242765612899, "analystOpinions": null, "businessSummary": "CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.", "enterpriseValue": 161574280000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 300000, "sharesOutstanding": 1272211063, "enterpriseToEbitda": 10.91791877829583, "analystTargetMedian": null, "enterpriseToRevenue": 3.418186972434365, "operatingCashflowTTM": 10639000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:22.684Z" }, "results": [ { "id": "cmnr139tl034lp658b2eqezjl", "runId": "cmnr139ti034fp658fkiqw012", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CVS\",\"currency\":\"USD\",\"current_price\":78.79,\"target_price_6m\":84.5,\"target_price_12m\":90.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward P/E of ~11x signals significant earnings recovery ahead\",\"FCF yield of ~13.8% is compelling relative to healthcare peers\",\"Aetna turnaround and cost restructuring should lift margins in 2026\",\"High leverage ($60.5B debt) constrains flexibility but is manageable with strong FCF\",\"Trailing EPS decline of 62% YoY creates low base for reversion\"],\"key_drivers\":[{\"driver\":\"Aetna medical loss ratio normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pharmacy benefit management competitive dynamics\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Enterprise cost restructuring and headcount optimization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Strong free cash flow supporting deleveraging\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 drug utilization boosting pharmacy revenue\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory/reimbursement rate pressure on pharmacy\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Debt service burden from Aetna acquisition\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield of 2.4% provides downside cushion\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Sustained elevated medical costs at Aetna compress insurance margins further\",\"PBM regulatory reform (e.g., FTC action) disrupts Caremark economics\",\"Debt refinancing risk if rates stay elevated, given $60.5B total debt\",\"Retail pharmacy foot traffic secular decline accelerates\",\"Management execution risk on multi-segment turnaround\",\"Medicare Advantage star ratings decline reducing bonus payments\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.055,\"wacc\":0.085,\"terminal_multiple\":11.0},\"scenarios\":{\"bear\":{\"target_price\":65.0,\"prob\":0.2,\"notes\":\"Aetna MLR stays elevated, EPS recovery stalls, multiple compresses to 9x forward.\"},\"base\":{\"target_price\":90.0,\"prob\":0.55,\"notes\":\"Earnings recover toward ~$7 forward EPS, market re-rates at ~12-13x forward P/E.\"},\"bull\":{\"target_price\":110.0,\"prob\":0.25,\"notes\":\"Strong margin expansion across all segments, deleveraging accelerates, multiple expands to 15x.\"}},\"method_notes\":\"Blended valuation: forward P/E (11-13x on ~$7 FY forward EPS) and FCF yield (9-10x ~$9.40 FCF/share). Base target ~$90 implies ~14% upside, supporting BUY. Trailing EPS depressed by Aetna cost headwinds; forward recovery is key catalyst. Debt overhang and execution risk cap confidence at 0.62. Sell-side targets noted but not used as numeric inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained elevated medical costs at Aetna compress insurance margins further", "PBM regulatory reform (e.g., FTC action) disrupts Caremark economics", "Debt refinancing risk if rates stay elevated, given $60.5B total debt", "Retail pharmacy foot traffic secular decline accelerates", "Management execution risk on multi-segment turnaround", "Medicare Advantage star ratings decline reducing bonus payments" ], "ticker": "CVS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Earnings recover toward ~$7 forward EPS, market re-rates at ~12-13x forward P/E.", "target_price": 90 }, "bear": { "prob": 0.2, "notes": "Aetna MLR stays elevated, EPS recovery stalls, multiple compresses to 9x forward.", "target_price": 65 }, "bull": { "prob": 0.25, "notes": "Strong margin expansion across all segments, deleveraging accelerates, multiple expands to 15x.", "target_price": 110 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 11, "ebit_margin_target": 0.055 }, "key_drivers": [ { "driver": "Aetna medical loss ratio normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Pharmacy benefit management competitive dynamics", "impact": "MED", "direction": "NEG" }, { "driver": "Enterprise cost restructuring and headcount optimization", "impact": "HIGH", "direction": "POS" }, { "driver": "Strong free cash flow supporting deleveraging", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 drug utilization boosting pharmacy revenue", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory/reimbursement rate pressure on pharmacy", "impact": "MED", "direction": "NEG" }, { "driver": "Debt service burden from Aetna acquisition", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield of 2.4% provides downside cushion", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended valuation: forward P/E (11-13x on ~$7 FY forward EPS) and FCF yield (9-10x ~$9.40 FCF/share). Base target ~$90 implies ~14% upside, supporting BUY. Trailing EPS depressed by Aetna cost headwinds; forward recovery is key catalyst. Debt overhang and execution risk cap confidence at 0.62. Sell-side targets noted but not used as numeric inputs. Not investment advice.", "current_price": 78.79, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of ~11x signals significant earnings recovery ahead", "FCF yield of ~13.8% is compelling relative to healthcare peers", "Aetna turnaround and cost restructuring should lift margins in 2026", "High leverage ($60.5B debt) constrains flexibility but is manageable with strong FCF", "Trailing EPS decline of 62% YoY creates low base for reversion" ], "target_price_6m": 84.5, "target_price_12m": 90 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 37159, "createdAt": "2026-04-09T05:20:22.900Z", "usage": { "inputTokens": 3651, "outputTokens": 1673, "costUsd": 0.06008 } }, { "id": "cmnr139tl034op65895dyww26", "runId": "cmnr139ti034fp658fkiqw012", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CVS\",\n \"currency\": \"USD\",\n \"current_price\": 78.79,\n \"target_price_6m\": 82.0,\n \"target_price_12m\": 85.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Integrated healthcare model drives cross-selling opportunities.\",\n \"Medicare Advantage growth supports revenue expansion.\",\n \"Cost efficiencies from scale improve margins.\",\n \"Regulatory headwinds pose significant risks.\",\n \"Current valuation discounts future earnings recovery.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"Healthcare services revenue growth\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"PBM margin stability\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Retail pharmacy traffic\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Debt reduction efforts\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Regulatory changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Competition in PBM market\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Integration of Aetna\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Drug pricing pressures\", \"impact\": \"HIGH\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\n \"High debt levels increasing financial risk.\",\n \"Adverse regulatory changes in healthcare.\",\n \"Integration failures from acquisitions.\",\n \"Intense competition reducing margins.\",\n \"Cybersecurity threats in healthcare data.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.055,\n \"wacc\": 0.08,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 75.0, \"prob\": 0.3, \"notes\": \"Regulatory pressures and margin compression.\"},\n \"base\": {\"target_price\": 85.0, \"prob\": 0.5, \"notes\": \"Steady growth and margin improvement.\"},\n \"bull\": {\"target_price\": 95.0, \"prob\": 0.2, \"notes\": \"Strong execution and market share gains.\"}\n },\n \"method_notes\": \"Valuation based on DCF with assumed growth and margins; expected return ~8% supports BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "High debt levels increasing financial risk.", "Adverse regulatory changes in healthcare.", "Integration failures from acquisitions.", "Intense competition reducing margins.", "Cybersecurity threats in healthcare data." ], "ticker": "CVS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth and margin improvement.", "target_price": 85 }, "bear": { "prob": 0.3, "notes": "Regulatory pressures and margin compression.", "target_price": 75 }, "bull": { "prob": 0.2, "notes": "Strong execution and market share gains.", "target_price": 95 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.04, "terminal_multiple": 10, "ebit_margin_target": 0.055 }, "key_drivers": [ { "driver": "Healthcare services revenue growth", "impact": "HIGH", "direction": "POS" }, { "driver": "PBM margin stability", "impact": "MED", "direction": "POS" }, { "driver": "Retail pharmacy traffic", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction efforts", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Competition in PBM market", "impact": "MED", "direction": "NEG" }, { "driver": "Integration of Aetna", "impact": "HIGH", "direction": "POS" }, { "driver": "Drug pricing pressures", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with assumed growth and margins; expected return ~8% supports BUY. Not investment advice.", "current_price": 78.79, "recommendation": "BUY", "thesis_bullets": [ "Integrated healthcare model drives cross-selling opportunities.", "Medicare Advantage growth supports revenue expansion.", "Cost efficiencies from scale improve margins.", "Regulatory headwinds pose significant risks.", "Current valuation discounts future earnings recovery." ], "target_price_6m": 82, "target_price_12m": 85 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 455, "createdAt": "2026-04-09T05:20:22.900Z", "usage": { "inputTokens": 2154, "outputTokens": 4345, "costUsd": 0.002428 } }, { "id": "cmnr139tl034mp658ghw8swbw", "runId": "cmnr139ti034fp658fkiqw012", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst v1.0\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CVS\",\n \"currency\": \"USD\",\n \"current_price\": 78.79,\n \"target_price_6m\": 83.00,\n \"target_price_12m\": 88.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Forward P/E of 11.2x prices in significant Medicare Advantage margin recovery.\",\n \"Strong FCF generation of $11.9B supports debt reduction and dividend sustainability.\",\n \"Retail pharmacy footprint optimization will gradually improve operating margins.\",\n \"Elevated medical loss ratios remain a near-term headwind for the Aetna segment.\",\n \"Vertical integration offers long-term cost synergies despite current regulatory scrutiny.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medicare Advantage MLR\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Pharmacy Services Volume\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cost-cutting Initiatives\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Retail Store Closures\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory Scrutiny on PBMs\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Debt Deleveraging\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Persistent elevation in senior outpatient utilization driving up Aetna's medical costs.\",\n \"Legislative action targeting Pharmacy Benefit Manager (PBM) pricing models.\",\n \"Slower than expected realization of Oak Street Health acquisition synergies.\",\n \"High debt load of $60.5B limits aggressive capital return flexibility.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.055,\n \"wacc\": 0.075,\n \"terminal_multiple\": 10.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 65.00,\n \"prob\": 0.25,\n \"notes\": \"Medical costs remain elevated and PBM legislation compresses margins.\"\n },\n \"base\": {\n \"target_price\": 88.00,\n \"prob\": 0.55,\n \"notes\": \"Aetna margins normalize and cost-cutting initiatives take hold.\"\n },\n \"bull\": {\n \"target_price\": 105.00,\n \"prob\": 0.20,\n \"notes\": \"Strong Medicare Advantage bid execution and rapid deleveraging drive multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 11.5x forward P/E and DCF (7.5% WACC, 10.5x terminal multiple). Upside of ~11.6% warrants a BUY rating, balancing strong FCF against near-term MLR risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Analyst v1.0", "risks": [ "Persistent elevation in senior outpatient utilization driving up Aetna's medical costs.", "Legislative action targeting Pharmacy Benefit Manager (PBM) pricing models.", "Slower than expected realization of Oak Street Health acquisition synergies.", "High debt load of $60.5B limits aggressive capital return flexibility." ], "ticker": "CVS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Aetna margins normalize and cost-cutting initiatives take hold.", "target_price": 88 }, "bear": { "prob": 0.25, "notes": "Medical costs remain elevated and PBM legislation compresses margins.", "target_price": 65 }, "bull": { "prob": 0.2, "notes": "Strong Medicare Advantage bid execution and rapid deleveraging drive multiple expansion.", "target_price": 105 } }, "confidence": 0.65, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.04, "terminal_multiple": 10.5, "ebit_margin_target": 0.055 }, "key_drivers": [ { "driver": "Medicare Advantage MLR", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pharmacy Services Volume", "impact": "MED", "direction": "POS" }, { "driver": "Cost-cutting Initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Retail Store Closures", "impact": "LOW", "direction": "POS" }, { "driver": "Regulatory Scrutiny on PBMs", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt Deleveraging", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a blend of 11.5x forward P/E and DCF (7.5% WACC, 10.5x terminal multiple). Upside of ~11.6% warrants a BUY rating, balancing strong FCF against near-term MLR risks. Not investment advice.", "current_price": 78.79, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 11.2x prices in significant Medicare Advantage margin recovery.", "Strong FCF generation of $11.9B supports debt reduction and dividend sustainability.", "Retail pharmacy footprint optimization will gradually improve operating margins.", "Elevated medical loss ratios remain a near-term headwind for the Aetna segment.", "Vertical integration offers long-term cost synergies despite current regulatory scrutiny." ], "target_price_6m": 83, "target_price_12m": 88 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25295, "createdAt": "2026-04-09T05:20:22.900Z", "usage": { "inputTokens": 2520, "outputTokens": 843, "costUsd": 0.015156 } }, { "id": "cmnr139tl034kp658hqzabnwx", "runId": "cmnr139ti034fp658fkiqw012", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CVS\",\"currency\":\"USD\",\"current_price\":78.79,\"target_price_6m\":84.5,\"target_price_12m\":90,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Forward P/E near 11x discounts managed-care margin pressure.\",\"Strong free cash flow supports deleveraging, dividend, and reinvestment.\",\"Diversified pharmacy, PBM, and insurance mix adds earnings resilience.\",\"Medicare repricing and cost actions can drive 2026 recovery.\",\"Debt, regulation, and medical-cost volatility limit rerating.\"],\"key_drivers\":[{\"driver\":\"Insurance margin stabilization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicare Advantage repricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"PBM and script volume growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cost reduction execution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Deleveraging progress\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated medical cost trend\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"PBM regulatory pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Retail front-store softness\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Medicare utilization remains above pricing assumptions.\",\"PBM reform or reimbursement cuts compress profits.\",\"Debt reduction is slower than expected.\",\"Execution missteps in insurance turnaround persist.\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.056,\"wacc\":0.085,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":68,\"prob\":0.25,\"notes\":\"Medical costs stay elevated and multiple remains depressed.\"},\"base\":{\"target_price\":90,\"prob\":0.5,\"notes\":\"Margins normalize gradually and cash flow supports modest rerating.\"},\"bull\":{\"target_price\":105,\"prob\":0.25,\"notes\":\"Insurance recovery and deleveraging drive stronger earnings confidence.\"}},\"method_notes\":\"Blended earnings-power and EV/EBIT view using snapshot quote/fundamentals and public context on managed-care repricing/utilization. Snapshot quote fields were not overridden; snapshot revenueTTM appears low versus company scale, so FCF, leverage and forward P/E were weighted more. Recommendation matches ~14% 12M upside. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "OpenAI o3", "risks": [ "Medicare utilization remains above pricing assumptions.", "PBM reform or reimbursement cuts compress profits.", "Debt reduction is slower than expected.", "Execution missteps in insurance turnaround persist." ], "ticker": "CVS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Margins normalize gradually and cash flow supports modest rerating.", "target_price": 90 }, "bear": { "prob": 0.25, "notes": "Medical costs stay elevated and multiple remains depressed.", "target_price": 68 }, "bull": { "prob": 0.25, "notes": "Insurance recovery and deleveraging drive stronger earnings confidence.", "target_price": 105 } }, "confidence": 0.64, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.055, "terminal_multiple": 10.5, "ebit_margin_target": 0.056 }, "key_drivers": [ { "driver": "Insurance margin stabilization", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare Advantage repricing", "impact": "HIGH", "direction": "POS" }, { "driver": "PBM and script volume growth", "impact": "MED", "direction": "POS" }, { "driver": "Cost reduction execution", "impact": "MED", "direction": "POS" }, { "driver": "Deleveraging progress", "impact": "MED", "direction": "POS" }, { "driver": "Elevated medical cost trend", "impact": "HIGH", "direction": "NEG" }, { "driver": "PBM regulatory pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Retail front-store softness", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended earnings-power and EV/EBIT view using snapshot quote/fundamentals and public context on managed-care repricing/utilization. Snapshot quote fields were not overridden; snapshot revenueTTM appears low versus company scale, so FCF, leverage and forward P/E were weighted more. Recommendation matches ~14% 12M upside. not investment advice", "current_price": 78.79, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E near 11x discounts managed-care margin pressure.", "Strong free cash flow supports deleveraging, dividend, and reinvestment.", "Diversified pharmacy, PBM, and insurance mix adds earnings resilience.", "Medicare repricing and cost actions can drive 2026 recovery.", "Debt, regulation, and medical-cost volatility limit rerating." ], "target_price_6m": 84.5, "target_price_12m": 90 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0efbf6ae2262c0370069d757e2084c819592c1785a8bb70a0c", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 33015, "createdAt": "2026-04-09T05:20:22.900Z", "usage": { "inputTokens": 2420, "outputTokens": 1843, "costUsd": 0.030037 } }, { "id": "cmnr139tl034np658ordimu5k", "runId": "cmnr139ti034fp658fkiqw012", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CVS\",\n \"currency\": \"USD\",\n \"current_price\": 78.79,\n \"target_price_6m\": 85,\n \"target_price_12m\": 94,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Forward P/E of 11x signals undervaluation vs peers\",\n \"Stable FCF supports debt paydown and dividends\",\n \"Aetna synergies offer multi-year margin expansion\",\n \"Recent EPS decline creates rebound opportunity\",\n \"High debt and regulatory risks cap upside\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Forward PE compression\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"FCF generation\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Aetna integration synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Total debt burden\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Revenue growth trajectory\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Healthcare regulation changes\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"PBM competitive intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend yield appeal\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Higher-for-longer interest rates on $60B debt\",\n \"Margin pressure from reimbursement cuts\",\n \"PBM contract losses to competitors\",\n \"Regulatory scrutiny on drug pricing\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.055,\n \"wacc\": 0.085,\n \"terminal_multiple\": 13\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 62,\n \"prob\": 0.3,\n \"notes\": \"Persistent margin erosion and lost contracts.\"\n },\n \"base\": {\n \"target_price\": 94,\n \"prob\": 0.5,\n \"notes\": \"Modest growth and stable multiple.\"\n },\n \"bull\": {\n \"target_price\": 118,\n \"prob\": 0.2,\n \"notes\": \"Strong synergies and market share gains.\"\n }\n },\n \"method_notes\": \"Blended forward EV/EBITDA comps and assumed 3Y DCF with 5% rev CAGR, 5.5% EBIT margin, 8.5% WACC, 13x terminal. 19% 12M upside supports BUY. Consensus targets noted but not used as input. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Higher-for-longer interest rates on $60B debt", "Margin pressure from reimbursement cuts", "PBM contract losses to competitors", "Regulatory scrutiny on drug pricing" ], "ticker": "CVS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest growth and stable multiple.", "target_price": 94 }, "bear": { "prob": 0.3, "notes": "Persistent margin erosion and lost contracts.", "target_price": 62 }, "bull": { "prob": 0.2, "notes": "Strong synergies and market share gains.", "target_price": 118 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 13, "ebit_margin_target": 0.055 }, "key_drivers": [ { "driver": "Forward PE compression", "impact": "HIGH", "direction": "POS" }, { "driver": "FCF generation", "impact": "HIGH", "direction": "POS" }, { "driver": "Aetna integration synergies", "impact": "MED", "direction": "POS" }, { "driver": "Total debt burden", "impact": "HIGH", "direction": "NEG" }, { "driver": "Revenue growth trajectory", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare regulation changes", "impact": "MED", "direction": "NEG" }, { "driver": "PBM competitive intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield appeal", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended forward EV/EBITDA comps and assumed 3Y DCF with 5% rev CAGR, 5.5% EBIT margin, 8.5% WACC, 13x terminal. 19% 12M upside supports BUY. Consensus targets noted but not used as input. Not investment advice.", "current_price": 78.79, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 11x signals undervaluation vs peers", "Stable FCF supports debt paydown and dividends", "Aetna synergies offer multi-year margin expansion", "Recent EPS decline creates rebound opportunity", "High debt and regulatory risks cap upside" ], "target_price_6m": 85, "target_price_12m": 94 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "bebf726c-bbef-96eb-ab5f-8017c49eb703", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 14793, "createdAt": "2026-04-09T05:20:22.900Z", "usage": { "inputTokens": 2758, "outputTokens": 2995, "costUsd": 0.053199 } } ] } }